Abstract 1640: Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach
Abstract 1640: Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach
复制标题
摘要 1640：利用肿瘤细胞的细胞骨架丝来增强一种新的治疗方法
DOI：
10.1158/1538-7445.am2015-1640
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Matthew R Trendowski
中科院分区：
文献类型：
--
作者：
Matthew R Trendowski
尽管细胞丝导向剂由于其能够容易地干扰肿瘤细胞的快速有丝分裂进展而成为化疗方案中的主要药物，但它们都是基于微管的药物，并且尚未有任何微管导向剂或中间体导向剂被批准用于临床使用。恶性肿瘤和正常细胞的细胞骨架网络之间存在许多固有差异，这为获得优先损伤提供了理想的靶点。此外，许多微生物导向剂和特别感兴趣的中间体微生物导向剂（醉茄素A）已经证明了体外和体内功效，表明细胞骨架丝可以用于补充目前在临床环境中使用的化疗方法。因此，这次谈话的目的是让学者和临床医生接触到目前可用于进一步化疗评估的各种各样的细胞骨架介导剂。微丝导向和中间体导向的药物损伤恶性细胞的机制将详细讨论，以确定如何将这些药物相互结合使用，或与目前批准的化疗药物联合使用，以产生实质性的协同攻击，可能建立一个新的化疗药物范例。注：本摘要未在会议上发表。利用肿瘤细胞的细胞骨架丝增强新的治疗方法。[摘要]。在：美国癌症研究协会第106届年会论文集; 2015年4月18日至22日;费城，宾夕法尼亚州。Philadelphia（PA）：AACR; Cancer Res 2015;75（15 Suppl）：Abstract nr 1640. doi：10.1158/1538-7445.AM2015-1640
Although cytoskeletal-directed agents have been a mainstay in chemotherapeutic protocols due to their ability to readily interfere with the rapid mitotic progression of neoplastic cells, they are all microtubule-based drugs, and there has yet to be any microfilament- or intermediate filament-directed agents approved for clinical use. There are many inherent differences between the cytoskeletal networks of malignant and normal cells, providing an ideal target to attain preferential damage. Further, numerous microfilament-directed agents, and an intermediate filament-directed agent of particular interest (withaferin A) have demonstrated in vitro and in vivo efficacy, suggesting that cytoskeletal filaments may be exploited to supplement chemotherapeutic approaches currently used in the clinical setting. Therefore, this talk is intended to expose academics and clinicians to the tremendous variety of cytoskeletal filament-directed agents that are currently available for further chemotherapeutic evaluation. The mechanisms by which microfilament directed- and intermediate filament-directed agents damage malignant cells will be discussed in detail in order to establish how the drugs can be used in combination with each other, or with currently approved chemotherapeutic agents to generate a substantial synergistic attack, potentially establishing a new paradigm of chemotherapeutic agents.Note:This abstract was not presented at the meeting.Citation Format:Matthew Trendowski. Exploiting the cytoskeletal filaments of neoplastic cells to potentiate a novel therapeutic approach. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1640. doi:10.1158/1538-7445.AM2015-1640